ALX Oncology (ALXO) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026ALX2004: EGFR antibody-drug conjugate
Phase I data expected in December 2026; the program was designed in-house, and clinical testing began ~12–13 months before the conference.
Matuzumab-derived binding epitope was selected based on prior clinical experience with fewer skin-related issues than cetuximab; the antibody internalizes at a similar rate to cetuximab.
Design priorities include reducing on-target rash, optimizing linker-payload potency and bystander effect, and keeping patients on treatment to enable payload delivery. No rash was seen in non-human primate studies.
Phase I study guidance increased to 35+ patients, including 15+ at relevant doses and in selected tumor types; enrollment shifted toward NSCLC and head and neck after reaching ~4 mg/kg.
Next development focus is second-line head and neck cancer and wild-type lung cancer, with assessment of EGFR-naive and EGFR-experienced patients; wild-type, especially squamous lung, was highlighted as an unmet-need setting.
Evorpacept: breast cancer phase II
ASPEN-09 is enrolling 120 patients with HER2-positive breast cancer to expand the data set before a potential phase III and refine the CD47 cut point.
The study uses HER2 status from archival or fresh tissue; sites are encouraged to obtain fresh biopsies, and ctDNA is also collected. Protocol CD47 status is defined as presence versus absence, with presence discussed as >5%.
Management estimated ~50% of enrolled patients may be confirmed HER2-positive and 50%–70% of those may be CD47-positive, depending on the cutoff.
The planned analysis compares outcomes by CD47 status; the primary endpoint discussed was response rate in HER2-confirmed, CD47-positive patients. Readout is expected in H2 2027.
Prior randomized gastric data showed increased response and durability with evorpacept added to a trastuzumab-based regimen; management cited real-world post-frontline HER2 treatment outcomes of 14%–15% ORR and 3–4 months’ PFS as a low benchmark.
Priorities and funding
Management said it aims to be nearing two registrational studies by this time next year, conditional on continued execution.
Management reported $159 million raised and stated cash runway through mid-2026, while describing funding as sufficient to reach key milestones.
Latest events from ALX Oncology
- Biomarker-led evorpacept and ALX2004 anchor catalysts through 2027.ALXO
Corporate presentation - Cash runway through H1 2028; evorpacept and ALX2004 data catalysts ahead.ALXO
Q3 2026 - Lead assets advance toward phase III, with strong biomarker focus and robust financial runway.ALXO
H.C. Wainwright 28th Annual Global Investment Conference - Biomarker-driven CD47 and novel EGFR ADC programs show promise for hard-to-treat cancers.ALXO
12th Annual Cantor Fitzgerald Global Healthcare Conference - ALX2004 and evorpacept advance toward registrational trials, targeting key oncology indications.ALXO
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028.ALXO
Q2 2026 - First randomized CD47 solid tumor trial shows strong efficacy, fueling expansion and partnership talks.ALXO
2024 Cantor Fitzgerald Global Healthcare Conference - Two high-value oncology programs advance toward pivotal data with strong financial support.ALXO
Jefferies London Healthcare Conference 2025 - Evorpacept plus PADCEV achieved a 59–62% response rate with favorable safety in advanced bladder cancer.ALXO
Study Update - Evorpacept advances in pivotal trials, extends cash runway, and prepares new ADC for the clinic.ALXO
Status Update